- Home
- JNVR vs CERO Comparison
JNVR vs CERO Comparison
Compare JNVR & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNVR
- CERO
- Stock Information
- Founded
- JNVR 2018
- CERO 2017
- Country
- JNVR United States
- CERO United States
- Employees
- JNVR N/A
- CERO N/A
- Industry
- JNVR Finance: Consumer Services
- CERO
- Sector
- JNVR Finance
- CERO
- Exchange
- JNVR Nasdaq
- CERO Nasdaq
- Market Cap
- JNVR 7.3M
- CERO 8.4M
- IPO Year
- JNVR 2023
- CERO N/A
- Fundamental
- Price
- JNVR $5.91
- CERO $2.23
- Analyst Decision
- JNVR
- CERO
- Analyst Count
- JNVR 0
- CERO 0
- Target Price
- JNVR N/A
- CERO N/A
- AVG Volume (30 Days)
- JNVR 23.6K
- CERO 872.3K
- Earning Date
- JNVR 11-06-2024
- CERO 02-20-2025
- Dividend Yield
- JNVR N/A
- CERO N/A
- EPS Growth
- JNVR N/A
- CERO N/A
- EPS
- JNVR N/A
- CERO N/A
- Revenue
- JNVR $1,820,969.00
- CERO N/A
- Revenue This Year
- JNVR N/A
- CERO N/A
- Revenue Next Year
- JNVR N/A
- CERO N/A
- P/E Ratio
- JNVR N/A
- CERO N/A
- Revenue Growth
- JNVR N/A
- CERO N/A
- 52 Week Low
- JNVR $3.37
- CERO $2.04
- 52 Week High
- JNVR $11.84
- CERO $1,280.00
- Technical
- Relative Strength Index (RSI)
- JNVR 57.98
- CERO 32.20
- Support Level
- JNVR $5.06
- CERO $2.21
- Resistance Level
- JNVR $6.70
- CERO $2.58
- Average True Range (ATR)
- JNVR 0.72
- CERO 1.04
- MACD
- JNVR -0.01
- CERO 0.10
- Stochastic Oscillator
- JNVR 63.76
- CERO 2.30
About JNVR Janover Inc.
Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from transaction fees.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.